HI-Bio
Signal active
Organization
Contact Information
Overview
Human Immunology Biosciences is a biotechnology company that focuses on developing therapies for immune-mediated diseases. The company's lead product, felzartamab, is a fully human anti-CD38 monoclonal antibody that has been shown in clinical studies to deplete CD38+ cells that include plasma cells and natural killer, or NK, cells which may allow for applications that improve clinical outcomes in a broad range of immune-mediated diseases.
About
Industries
Biotechnology, Life Science, Medical, Therapeutics, Product Research
Founded
2021
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
HI-Bio headquartered in United States, North America, operates in the Biotechnology, Life Science, Medical, Therapeutics, Product Research sector. The company focuses on Biotechnology and has secured $8.6B in funding across 40 round(s). With a team of 11-50 employees, HI-Bio is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - HI-Bio, raised $95.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
2
Investors
5
Lead Investors
0
Total Funding Amount
$215.0M
Details
2
HI-Bio has raised a total of $215.0M in funding over 2 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2022 | Early Stage Venture | 120.0M | ||
| 2024 | Early Stage Venture | 95.0M |
Investors
HI-Bio is funded by 22 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Carol Suh | - | FUNDING ROUND - Carol Suh | 95.0M |
| Paul L Berns | - | FUNDING ROUND - Paul L Berns | 95.0M |
| HI-Bio | - | FUNDING ROUND - HI-Bio | 95.0M |
| ARCH Venture Partners | - | FUNDING ROUND - ARCH Venture Partners | 95.0M |
Recent Activity
There is no recent news or activity for this profile.